MedPath

AJU PHARM CO., LTD.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:1
Completed:5

Trial Phases

5 Phases

Phase 1:7
Phase 2:1
Phase 3:3
+2 more phases

Drug Approvals

19

PHILIPPINES:19

Drug Approvals

Afeclor

Approval Date
Jul 14, 2025
PHILIPPINES

Anarica

Approval Date
Jul 14, 2025
PHILIPPINES

Zevas

Approval Date
Jul 14, 2025
PHILIPPINES

Noreph

Approval Date
Jul 14, 2025
PHILIPPINES

Sephrine

Approval Date
Jul 14, 2025
PHILIPPINES

Gifixon

Approval Date
Jul 14, 2025
PHILIPPINES

Trampro

Approval Date
Jul 14, 2025
PHILIPPINES

Cobis

Approval Date
Jul 14, 2025
PHILIPPINES

Adrenapin

Approval Date
Jul 14, 2025
PHILIPPINES

Citicol-1000

Approval Date
Jul 14, 2025
PHILIPPINES
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (53.8%)
Phase 3
3 (23.1%)
Not Applicable
1 (7.7%)
Phase 2
1 (7.7%)
Phase 4
1 (7.7%)

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

Not Applicable
Not yet recruiting
Conditions
Type2 Diabetes Mellitus
Interventions
Drug: Comparator 1
Drug: Comparator 2
Drug: Test Drug
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
AJU Pharm Co., Ltd.
Target Recruit Count
32
Registration Number
NCT07044765
Locations
🇰🇷

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Phase 1
Not yet recruiting
Conditions
Type2 Diabetes Mellitus
Interventions
Drug: Comparator 1
Drug: Comparator 2
Drug: Test Drug
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
AJU Pharm Co., Ltd.
Target Recruit Count
50
Registration Number
NCT07034781
Locations
🇰🇷

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of

To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults

Phase 1
Active, not recruiting
Conditions
Dyslipidemia
Interventions
Drug: Test Drug
Drug: Reference Drug
First Posted Date
2025-04-18
Last Posted Date
2025-06-12
Lead Sponsor
AJU Pharm Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06933459
Locations
🇰🇷

H+ Yangji Hospital, Seoul, Republic of South Korea, Seoul, Korea, Republic of

To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults

Phase 1
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Test Drug
Drug: Reference Drug
First Posted Date
2025-04-17
Last Posted Date
2025-06-12
Lead Sponsor
AJU Pharm Co., Ltd.
Target Recruit Count
60
Registration Number
NCT06931327
Locations
🇰🇷

Bumin Hospital, Seoul, Republic of South Korea, Seoul, Korea, Republic of

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

Phase 3
Recruiting
Conditions
Essential Hypertension
Interventions
Drug: AJU-C52L, AJU-C52
Drug: C52R1L, C52R1M
First Posted Date
2024-05-16
Last Posted Date
2024-05-22
Lead Sponsor
AJU Pharm Co., Ltd.
Target Recruit Count
190
Registration Number
NCT06416865
Locations
🇰🇷

AJU Pharm Co., Ltd., Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.